RARA

Across TCGA pan-cancer cohorts, RARA mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RARA’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RARA mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RARA is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where RARA tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RARA mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.687	<.001	9	view →
HNSC	Male	IV	+0.575	<.001	8	view →
LSCC	All	III,IV	−0.409	<.001	8	view →
LUAD	Male	II,III,IV	+0.359	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

RARA–CCRCC

Open the CCRCC breakdown →